The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease

Acta Ophthalmologica

Volumn 90, Issue 8, 2012, Pages

  Abu El Asrar, Ahmed M ^a   Hemachandran, Suhail ^a   Al Mezaine, Hani S ^a   Kangave, Dustan ^a   Al Muammar, Abdulrahman M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

complications; immunomodulatory therapy; mycophenolate mofetil; recurrence; Vogt Koyanagi Harada disease

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE UVEITIS; ADULT; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PERCEPTION DEAFNESS; POLIOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SUNSET GLOW FUNDUS; UVEITIS; VISUAL ACUITY; VITILIGO; VOGT KOYANAGI SYNDROME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; COLORING AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOCYANINE GREEN; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; OPHTHALMOSCOPY; PREDNISONE; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; UVEITIS, POSTERIOR; UVEOMENINGOENCEPHALITIC SYNDROME; VISUAL ACUITY; YOUNG ADULT;

EID: 84870489861     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2012.02498.x     Document Type: Article

References (34)

1. Abu El-Asrar AM, Al-Kharashi AS, Aldibhi H, et al., (2008): Vogt-Koyanagi-Harada disease in children. Eye (Lond) 22: 1124-1131.
2. Abu El-Asrar AM, Struyf S, Kangave D, et al., (2011): Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol 139: 177-184.
3. Al-Kharashi AS, Aldibhi H, AL-Fraykh H, et al., (2007): Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol 27: 201-210.
4. Al-Mezaine HS, Kangave D, &, Abu El-Asrar AM, (2010): Patterns of uveitis in patients admitted to a university hospital in Riyadh, Saudi Arabia. Ocul Immunol Inflamm 18: 424-431.
5. Appel GB, Radhakrishnan J, &, Ginzler EM, (2005): Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 80 (2 Suppl.): S265-S271.
6. Bacsal K, Wen DS, &, Chee SP, (2008): Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 145: 480-486.
7. Baltazis S, Tufail F, Yu EN, et al., (2003): Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110: 1061-1065.
8. Chee SP, Jap A, &, Bacsal K, (2007): Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol 27: 137-142.
9. Cuchacovich M, Solanes F, Diaz G, et al., (2010): Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 18: 200-207.
10. Daniel E, Thorne JE, Newcomb CW, et al., (2010): Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 149: 423-432.
11. Errera MH, Fardeau C, Cohen D, et al., (2011): Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt-Koyanagi-Harada disease. Acta Ophthalmol 89: e357-e366.
12. Fang W, &, Yang P, (2008): Vogt-Koyanagi-Harada syndrome. Curr Eye Res 33: 517-523.
13. Fang W, Zhou H, Yang P, et al., (2008): Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 92: 182-185.
14. Gocho K, Kondo I, &, Yamaki K, (2001): Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 42: 2004-2009.
15. Jabs DA, Nussanblatt RB, Rosenbaum JT, & Standardization of Uveitis Nomenclature (SUN) Working Group (2005): Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140: 509-516.
16. Kawaguchi T, Horie S, Bouchenaki N, et al., (2010): Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Int Ophthalmol 30: 41-50.
17. Keino H, Goto H, &, Usui M, (2002): Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. Graefes Arch Clin Exp Ophthalmol 240: 878-882.
18. Keino H, Goto H, Mori H, et al., (2006): Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 141: 1140-1142.
19. Kim SJ, &, Yu HG, (2007): The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 15: 381-387.
20. Lai TY, Chan RP, Chan CK, &, Lam DS, (2009): Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (Lond) 23: 543-548.
21. Lau CH, Comer M, &, Lightman S, (2003): Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 31: 487-491.
22. Moorthy RS, Inomata H, &, Rao NA, (1995): Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39: 265-292.
23. Ohno S, Char DH, Kimura SJ, &, O'Connor GR, (1977): Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 83: 735-740.
24. Ohno S, Minakawa R, &, Matsuda H, (1988): Clinical studies of Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 32: 334-343.
25. Paredes I, Ahmed M, &, Foster CS, (2006): Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm 14: 87-90.
26. Read RW, Holland GN, Rao NA, et al., (2001a): Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131: 647-652.
27. Read RW, Rechodouni A, Butani N, et al., (2001b): Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131: 599-606.
28. Rubsamen PE, &, Gass JD, (1991): Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol 109: 682-687.
29. Siepmann K, Huber M, Sübiger N, et al., (2006): Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 244: 788-794.
30. Srinivas TR, Kaplan B, &, Meier-Kriesche HU, (2003): Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 4: 2325-2345.
31. Teoh SC, Hogan AC, Dick AD, &, Lee RW, (2008): Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 146: 752-760.
32. Yamaki K, Gocho K, Hayakawa K, et al., (2000a): Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 165: 7323-7329.
33. Yamaki K, Kondo I, Nakamura H, et al., (2000b): Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res 71: 361-369.
34. Yang P, Ren Y, Li B, et al., (2007): Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology 114: 606-614.